Curis (CRIS) Short term Debt (2013 - 2025)

Curis' (CRIS) quarterly Short term Debt came in at $7.0 million in Q3 2025, down 5.47% on a QoQ basis from $7.4 million in Q2 2025.

Curis (CRIS) Short term Debt (2013 - 2025) Analysis & Trends

Curis (CRIS) has 11 years of Short term Debt data on file, last reported at $7.0 million in Q3 2025.

Quarterly Short term Debt changed N/A year-over-year to $7.0 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $7.0 million (changed N/A YoY) and the FY2024 annual result came in at $7.6 million, down 11.15% from the prior year.
Short term Debt retreated to $7.0 million in Q3 2025, from $7.4 million in the prior quarter.
In the past five years, Short term Debt ranged from a high of $8.5 million in Q4 2023 to a low of $891000.0 in Q1 2021.
A 4-year average of $6.4 million and a median of $7.3 million in 2025 frame the typical range for Short term Debt.
The widest YoY moves for Short term Debt: up 11.15% in 2024, down 11.15% in 2024.
Tracing CRIS's Short term Debt over 4 years: stood at $891000.0 in 2021, then jumped by 854.43% to $8.5 million in 2023, then retreated by 11.15% to $7.6 million in 2024, then retreated by 8.01% to $7.0 million in 2025.
The last three Short term Debt figures came in at $7.0 million (Q3 2025), $7.4 million (Q2 2025), and $7.2 million (Q1 2025), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn
10	Curis	3.44 Mn	-2.18 Mn	-

Download Data